DK2144889T3 - Quinazolin-oxim derivater som HSP90 inhibitorer - Google Patents
Quinazolin-oxim derivater som HSP90 inhibitorerInfo
- Publication number
- DK2144889T3 DK2144889T3 DK08763865.6T DK08763865T DK2144889T3 DK 2144889 T3 DK2144889 T3 DK 2144889T3 DK 08763865 T DK08763865 T DK 08763865T DK 2144889 T3 DK2144889 T3 DK 2144889T3
- Authority
- DK
- Denmark
- Prior art keywords
- quinazoline
- hsp90 inhibitors
- oxime derivatives
- oxime
- derivatives
- Prior art date
Links
- -1 Quinazoline oxime Chemical class 0.000 title 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0709534A GB2449293A (en) | 2007-05-17 | 2007-05-17 | Compounds having Hsp90 inhibitory activity |
PCT/IT2008/000326 WO2008142720A2 (en) | 2007-05-17 | 2008-05-15 | Quinazolin-oxime derivatives as hsp90 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2144889T3 true DK2144889T3 (da) | 2012-12-17 |
Family
ID=38234648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08763865.6T DK2144889T3 (da) | 2007-05-17 | 2008-05-15 | Quinazolin-oxim derivater som HSP90 inhibitorer |
Country Status (13)
Country | Link |
---|---|
US (1) | US8592430B2 (da) |
EP (1) | EP2144889B1 (da) |
JP (1) | JP5425057B2 (da) |
CN (1) | CN101720318B (da) |
AU (1) | AU2008252380B2 (da) |
CA (1) | CA2687283A1 (da) |
DK (1) | DK2144889T3 (da) |
ES (1) | ES2394472T3 (da) |
GB (1) | GB2449293A (da) |
HK (1) | HK1143367A1 (da) |
MX (1) | MX2009012418A (da) |
RU (1) | RU2009146832A (da) |
WO (1) | WO2008142720A2 (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
DE102008061214A1 (de) * | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
US8722939B2 (en) | 2009-10-29 | 2014-05-13 | Northwestern University | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
ITTO20111013A1 (it) * | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
AU2013266086B2 (en) | 2012-05-25 | 2018-03-01 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
WO2015023593A1 (en) | 2013-08-12 | 2015-02-19 | Emory University | Progesterone phosphate analogs and uses related thereto |
AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3390368A4 (en) * | 2015-12-17 | 2019-07-03 | ArQule, Inc. | PROCESS FOR PREPARING SUBSTITUTED 5,6-DIHYDRO-6-PHENYL BENZO [F] ISOCHINOLINE-2-AMINE |
WO2017189553A1 (en) * | 2016-04-25 | 2017-11-02 | Everon Biosciences, Inc. | Removal of senescence-associated macrophages |
CN108947985A (zh) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | 用作自噬调节剂的化合物及其制备方法和用途 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN114259564B (zh) * | 2021-11-30 | 2023-03-14 | 清华大学 | Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5536725A (en) * | 1993-08-25 | 1996-07-16 | Fmc Corporation | Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines |
AU2006236557A1 (en) * | 2005-04-14 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases |
DE102005022977A1 (de) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
GB0519245D0 (en) * | 2005-09-20 | 2005-10-26 | Vernalis R&D Ltd | Purine compounds |
JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
DE102006008880A1 (de) * | 2006-02-27 | 2007-09-06 | Merck Patent Gmbh | Aminopyrimidinderivate |
WO2008024961A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors |
WO2008045529A1 (en) * | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
ES2475206T3 (es) * | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
-
2007
- 2007-05-17 GB GB0709534A patent/GB2449293A/en not_active Withdrawn
-
2008
- 2008-05-15 MX MX2009012418A patent/MX2009012418A/es active IP Right Grant
- 2008-05-15 US US12/599,116 patent/US8592430B2/en not_active Expired - Fee Related
- 2008-05-15 ES ES08763865T patent/ES2394472T3/es active Active
- 2008-05-15 EP EP08763865A patent/EP2144889B1/en not_active Not-in-force
- 2008-05-15 RU RU2009146832/04A patent/RU2009146832A/ru not_active Application Discontinuation
- 2008-05-15 CA CA002687283A patent/CA2687283A1/en not_active Abandoned
- 2008-05-15 AU AU2008252380A patent/AU2008252380B2/en not_active Ceased
- 2008-05-15 JP JP2010508032A patent/JP5425057B2/ja not_active Expired - Fee Related
- 2008-05-15 CN CN200880023140.3A patent/CN101720318B/zh not_active Expired - Fee Related
- 2008-05-15 DK DK08763865.6T patent/DK2144889T3/da active
- 2008-05-15 WO PCT/IT2008/000326 patent/WO2008142720A2/en active Application Filing
-
2010
- 2010-10-18 HK HK10109849.2A patent/HK1143367A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2008142720A3 (en) | 2009-01-08 |
CN101720318A (zh) | 2010-06-02 |
CN101720318B (zh) | 2014-03-12 |
WO2008142720A2 (en) | 2008-11-27 |
CA2687283A1 (en) | 2008-11-27 |
US8592430B2 (en) | 2013-11-26 |
MX2009012418A (es) | 2010-03-10 |
JP5425057B2 (ja) | 2014-02-26 |
EP2144889A2 (en) | 2010-01-20 |
US20110118258A1 (en) | 2011-05-19 |
AU2008252380B2 (en) | 2013-05-02 |
JP2010527348A (ja) | 2010-08-12 |
HK1143367A1 (en) | 2010-12-31 |
WO2008142720A4 (en) | 2009-03-05 |
RU2009146832A (ru) | 2011-06-27 |
AU2008252380A1 (en) | 2008-11-27 |
GB0709534D0 (en) | 2007-06-27 |
GB2449293A (en) | 2008-11-19 |
EP2144889B1 (en) | 2012-08-29 |
ES2394472T3 (es) | 2013-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2144889T3 (da) | Quinazolin-oxim derivater som HSP90 inhibitorer | |
CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
ZA201005435B (en) | Oxim derivatives as hsp90 inhibitors | |
DK2315756T3 (da) | 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase | |
DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
DK2069324T3 (da) | Fusioneret aminopyridin som hsp90-inhibitorer | |
DK2081895T3 (da) | Hydrobenzamidderivater som hæmmere af hsp90 | |
DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
DK2164844T3 (da) | Pyrimidinyl-pyridazinonderivater | |
DK2209786T3 (da) | Pyrimidinsubstituerede purinderivater | |
DK2139892T3 (da) | Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer | |
DK2125748T3 (da) | Acylaminopyrazol som FGFR inhibitorer | |
DK2178840T3 (da) | Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere | |
DK2094263T3 (da) | 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer | |
ATE469905T1 (de) | Pyridopyrimidinonderivate | |
DK1981892T3 (da) | Thienopyridinderivater som mek-inhibitorer | |
DK2078001T3 (da) | Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer | |
ATE518837T1 (de) | Indazolamidderivate | |
CR10879A (es) | Cyclized derivatives as eg-5 inhibitors | |
DK2152370T3 (da) | Aryletherpyridazinonderivater | |
DK2318378T3 (da) | Quinazolin-derivater | |
DK2142533T3 (da) | Imidazolidinonderivater | |
DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
ATE519760T1 (de) | Isoxazolimidazolderivate | |
JP2009543766A5 (ja) | mPGEs−1阻害剤としての2−アリールインドール誘導体 |